10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Saturday, June 13, 2009

Alembic Ltd:-A dark horse in the pharma sector

Scripscan:Alembic Ltd
Traded in:Nse-bse

Story:With a turnover of Rs 1,000 crore, Vadodara-based Alembic is one of the oldest pharma companies. It lost out on growth to other players during the 1990s. The company, now managed by fourth-generation promoters, is restructuring its operations to catch up on lost opportunities. Alembic is an integrated manufacturer of formulations and active pharma ingredients (APIs) with 70% of its business coming from the domestic market.Its formulations business, consisting of generic as well as branded formulations, accounts for 70% of its total revenue, while APIs contribute the remaining. The company spends 4.5% of its sales towards R&D. It is involved in generic research, innovative research towards novel drug delivery systems (NDDS) and undertaking bio-equivalence studies. Recently, it entered into an out-licensing deal for its NDDS for Keppra XR, a leading anti-epileptic drug, with Belgium-based innovator company, UCB Pharma.Alembic has adopted a dual-pronged strategy of new products for existing geographies and existing products for new geographies. While anti-infectives contribute more than 50% to its domestic formulation sales, the company has broad-based its product portfolio to include products from high growth chronic therapeutic areas like respiratory, orthopaedic and gynaecology. The acquisition of Dabur Pharma?s non-oncology business in January ?07 helped the company to include more such products in its portfolio.Alembics global strategy is to be the preferred supply chain partner to multinational pharma companies. Towards this, it has been investing in FDA-approved manufacturing facilities and research centres. Through these initiatives, the company aims to increase its share of international business to nearly half of its revenues over the next 2-3 years.The company has restructured its domestic business and invested heavily in acquiring new products, building up field force and creating new business divisions. While this has had a negative impact on its profitability during the first two quarters of this fiscal, the company expects the full benefits of restructuring to be visible in FY10.Alembic has land bank of 50 acres, which it plans to monetise in future to boost its cash flows. It is also considering acquisitions to expedite its growth.WHEN A 100-year-old business undertakes restructuring to unlock its hidden value, it offers an attractive opportunity for investors to pick up assets at value for money prices.Alembic is one such company that is transforming itself from a pure domestic pharmaceutical company to a complete pharma company, with a presence across the entire pharma value chain.Considering all these its a great buy at dips.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner